No. Stem cells are living cells that can self-renew and develop into specialized cells; exosomes are vesicles released by cells, not cells themselves. A stem cell’s ability to specialize depends on its type Stc basics. Exosomes carry molecules such as proteins, lipids and RNA, but cannot reproduce independently. “Stem cell-derived exosomes” describes where the vesicles came from, not living stem cells inside them Jev2.12404.
The distinction matters when comparing treatments: evidence for a living-cell therapy does not establish that an exosome product works. The FDA consumer alert states that there are no FDA-approved exosome products Consumer alert regenerative medicine products including stem cells and exosomes. In one 2024 knee-osteoarthritis trial, 31 patients were enrolled, and a placental cell-derived EV injection showed no statistically significant advantage over saline at 6 months. That was an EV-versus-saline study, not a comparison with living stem cells S12891 024 07979 w.

Stem cells versus exosomes
| Feature | Stem cells | Exosomes |
|---|---|---|
| What they are | Living cells capable of self-renewal and differentiation | Membrane-bound vesicles released by cells |
| Can they divide? | Yes, under suitable conditions | No independent replication |
| Can they become another cell type? | Yes, within the limits of the stem cell type | No |
| What they contain | A nucleus, DNA, organelles and cytoplasm | Molecular cargo, including proteins, lipids and RNA; no functional nucleus |
| Where they come from | Sources include bone marrow, fat and cord blood | Many cell types, including stem cells |
| Role being used or studied | Blood-forming cells can restore blood production; other cell products may act through immune effects | Cell communication and experimental therapeutic delivery, not replacement cells |
These are biological differences, not a ranking of which treatment is better. The definitions come from NIH and the International Society for Extracellular Vesicles; established blood-stem-cell transplantation is described by NCI Stc basicsJev2.12404Stem cell transplant.
What stem cells can do
Blood-forming stem cells produce red cells, white cells and platelets. In a transplant, they are infused into a vein and establish blood production in the marrow after treatment such as high-dose chemotherapy. This is used for selected blood cancers and other disorders, not as a general rejuvenation procedure. Risks include infection, bleeding and, with donor cells, graft-versus-host disease, which can damage organs Stem cell transplant.
Mesenchymal stromal cells (MSCs) are a different cell category. In December 2024, the FDA approved Ryoncil, a donor-derived bone marrow MSC therapy, for steroid-refractory acute graft-versus-host disease in children aged 2 months and older. Its multicenter, single-arm study included 54 children: 30% had a complete response and 41% a partial response at day 28. Participants received intravenous infusions twice weekly for four weeks. Common adverse reactions included infections, fever and hemorrhage. This approval is specific to the product and indication; it does not validate other MSC products or exosomes Fda approves first mesenchymal stromal cell therapy treat steroid refractory acute graft versus host.
What exosomes are
Extracellular vesicle (EV) is the broader term for a lipid-bilayer particle released by a cell that cannot replicate on its own. Exosomes are a subtype formed through the cell’s endosomal pathway. MISEV2023 recommends using “EV” unless there is evidence for the more specific origin. A particle’s small size or a product label alone does not establish that it is an exosome Jev2.12404.
A cell is like a workshop; a vesicle is more like an envelope it sends out. The envelope can carry instructions, but it is not another workshop. EVs can affect recipient cells, which is why they are being studied as biomarkers, delivery carriers and experimental therapies. Laboratory or animal findings do not establish patient benefit Jev2.12404.
Are stem cell-derived exosomes stem cells?
No. “Stem cell-derived” identifies the source cells. It does not mean an exosome can divide, turn into tissue or contain a stem cell. Nor does the name establish the composition of a finished vial: the preparation and separation methods affect which vesicles and other substances remain Jev2.12404.
Conditioned medium is different again. It is the liquid collected after cells have been cultured and can contain secreted proteins and EVs; it is not automatically an isolated exosome preparation. Japan’s July 2024 health-ministry notice addresses both stem-cell culture supernatant and exosome-related products, warning that their use requires particular attention to safety 001281987.pdf.
Are exosomes better than stem cells?
The evidence discussed here does not establish that one is generally better. A transplant for a blood disorder, an MSC medicine for graft-versus-host disease and an experimental EV injection for knee arthritis involve different patients, products and outcomes. Ryoncil’s day-28 response rate cannot be compared with a knee trial’s six-month pain scores as if they were competing treatments Stem cell transplantFda approves first mesenchymal stromal cell therapy treat steroid refractory acute graft versus hostS12891 024 07979 w.
What the human knee trial found
The 2024 randomized, triple-blind trial in Iran enrolled 31 adults with bilateral Kellgren–Lawrence grade 2–3 knee osteoarthritis, or 62 knees. In each person, one knee received a single intra-articular injection of placental MSC-derived EVs, 5 mL at 7 × 109 particles/mL, and the other received 5 mL saline. The six-month analysis included 29 people and 58 knees. Those 29 participants included 28 women and 1 man, with a mean age of 55.38 years S12891 024 07979 w.
There was no statistically significant between-group difference in VAS pain, WOMAC or Lequesne scores at 2 or 6 months, or in MRI findings at 6 months. No systemic complications or severe local reactions were reported. Four of the 31 patients, about 13%, had moderate pain with mild warmth that improved within 48 hours with cold compresses and paracetamol. The study was too small to exclude rare harms, and its results apply to this preparation, dose, route and follow-up—not every EV product S12891 024 07979 w.
How to read those numbers
This paper gives a useful real-world reading example: 62 knees did not mean 62 independent patients. Each person contributed an EV-treated knee and a saline-treated knee, and the final analysis covered 29 people rather than all 31 enrolled. Also, “no statistically significant difference” does not prove that two treatments are equivalent. Most importantly, this study cannot answer whether EVs outperform living MSCs, because it had no living-cell treatment arm S12891 024 07979 w.
A 2024 systematic review pooled 21 reports of human EV therapy and estimated serious adverse events at 0.7% (95% confidence interval 0.1–5.2%). The products, study designs and adverse-event reporting methods differed. That pooled estimate is not a risk estimate for a particular clinic’s injection and is not proof of efficacy Jev2.12458.
Are cell-free products safer?
Not necessarily. “Cell-free” does not mean sterile, consistent or clinically proven. In 2019, the FDA reported serious adverse events in Nebraska after unapproved products marketed as containing exosomes; the CDC described bacterial infections among affected patients Public safety notification exosome productsStem cell products.
Japan’s regenerative-medicine society identifies potential risks including infection, unwanted immune responses, impurities, unintended distribution and organ toxicity. Its guidance also discusses tumors or unwanted tissue arising from the recipient’s own cells. That is a risk to assess, not a measured cancer rate after EV treatment, and it differs from abnormal growth of living cells in an administered cell product. Manufacturing, transport and storage can affect the preparation News14993 2.pdf.
Before any procedure, discuss the product and a plan for complications with a qualified clinician; safety planning in Japan also requires understanding the local care arrangements. If a reaction occurs, seek medical care first. In the US, adverse events can be reported through FDA MedWatch. Do not stop established treatment to try an unproven product without discussing the risks with your treating clinician Public safety notification exosome products.
Approval in the US and Japan
The regulatory statements below are tied to the cited documents, not a claim about every country or every subsequent approval. The FDA consumer alert, last updated April 9, 2024, says exosome products intended to treat disease generally require FDA approval and that none are FDA-approved. Its older wording about which stem-cell products are approved must be read alongside the later December 2024 Ryoncil approval Consumer alert regenerative medicine products including stem cells and exosomesFda approves first mesenchymal stromal cell therapy treat steroid refractory acute graft versus host.
“FDA registered” is not the same as “FDA approved.” Registration does not establish that a product works Stem cell products.
For a US exosome study, ask for the FDA-issued Investigational New Drug application number and the FDA acknowledgment, as well as the ethics-board details and informed-consent form. A trial registry entry alone does not establish authorization or benefit Public safety notification exosome products.
In Japan, covered cell procedures use a provision-plan and certified-committee review process under the Act on the Safety of Regenerative Medicine. This is separate from marketing authorization for a manufactured product; a filed plan does not establish efficacy En.
MHLW’s July 31, 2024 reagent notice says exosome reagents are not approved medicines and that products promoted for disease treatment can be treated as unapproved drugs. Its same-day provider notice warns about safety and refers providers to the society guidance T_doc?dataId=00tc8664&dataType=1&pageNo=1001281987.pdf. The society’s 2024 guidance describes doctor-prepared EV therapy for patients at the same institution as outside that Act’s certified-committee review process. This dated description is not evidence that the service is approved or risk-free News14993 2.pdf.
An FY2025 MHLW research report describes MSC-EV trials at phase II/III and unresolved quality and oversight issues. It is a research report, not a treatment authorization 001705475.pdf. PMDA’s approved-product list covering April 2015 through July 2026 includes TEMCELL for acute graft-versus-host disease but lists no exosome product. That list is a dated regulatory snapshot, not a global approval survey 000283257.pdf.
A provision plan and committee review are not a product marketing authorization En.
What a clinic’s product name tells you
| Label | What it describes | What still needs checking |
|---|---|---|
| Stem cell or MSC therapy | A preparation intended to contain living cells | Exact cell source, viable-cell dose, manufacturing controls and authorization for the proposed use |
| Conditioned medium | Liquid collected from a cell culture, not automatically purified EVs | Whether cells were removed, composition and clinical evidence for the finished preparation |
| Exosome or EV preparation | A preparation intended to contain released vesicles | Vesicle identity, contaminants, dose, sterility and evidence for the proposed route and disease |
| Exosome cosmetic | A skin product using exosome terminology | Actual ingredients and intended use; a cosmetic label does not establish approval as a disease treatment |
A name alone cannot establish a vial’s contents or a treatment’s legal status. EV characterization guidance and Japan’s notice on culture supernatant explain why cell-derived material should not be treated as one interchangeable product category Jev2.12404001281987.pdf. Particle measurements and quality tests help describe a preparation, but do not by themselves prove clinical benefit News14993 2.pdf.
Questions before considering treatment
If a clinic offers “stem cell exosomes,” ask it to identify the actual material before discussing expected benefits. Bring the written product description and proposed treatment plan to your own clinician so you can check the following points together.
- Is the proposed treatment living cells, conditioned medium, isolated EVs or a mixture?
- What batch-specific data show identity, dose, sterility and endotoxin testing?
- Are the source cells mine or a donor’s, and how were they screened?
- What approval or research authorization covers this exact product and intended use?
- What human studies match my condition, the product, dose and route? What were the comparator, outcomes and follow-up?
- What risks are known, what remains uncertain, and who manages complications?
- What established alternatives are available, and what could happen if I delay them?
- Does the clinic promise a cure or guaranteed rejuvenation? Such claims need scrutiny, not acceptance as evidence.
Bottom line
Stem cells and exosomes are not the same, and an exosome product is not a substitute for an approved cell therapy merely because it came from stem cells. The 2024 knee trial enrolled 31 people and analyzed 29 at six months, without finding a statistically significant advantage for EVs over saline; it did not compare EVs with living cells. Ask for evidence on the exact preparation and proposed use rather than relying on the category name Jev2.12404S12891 024 07979 w.
Questions about treatment information in Japan?
Use our contact form to ask about the information or documents you need. Treatment suitability and medical decisions should be discussed with a qualified clinician.
This article provides general educational information, not a diagnosis, a treatment recommendation or a substitute for medical advice.




